Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 65 | 218 | 832 | 10,262 | 1,775 |
| Gross Profit | 65 | 218 | 832 | 10,262 | 1,775 |
| Operating Expenses | 86,888 | 112,617 | 144,772 | 277,836 | 302,993 |
| Operating Income | -86,822 | -112,399 | -143,940 | -267,574 | -301,218 |
| Interest Expense | 0 | 178 | 1,223 | 1,254 | 1,936 |
| Other Income | 1,876 | 5,323 | 10,045 | -8,825 | -70 |
| Pre-tax Income | -84,946 | -107,254 | -135,117 | -277,653 | -303,224 |
| Income Tax | N/A | N/A | N/A | 2,165 | 434 |
| Net Income Continuous | -84,946 | -107,254 | -135,117 | -279,818 | -303,659 |
| Net Income | $-84,946 | $-107,254 | $-135,117 | $-279,818 | $-303,659 |
| EPS Basic Total Ops | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| EPS Basic Continuous Ops | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| EPS Diluted Total Ops | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| EPS Diluted Continuous Ops | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| EPS Diluted Before Non-Recurring Items | -1.80 | -4.05 | -5.62 | -14.05 | -17.41 |
| EBITDA(a) | $-83,836 | $-110,959 | $-127,939 | $-263,398 | $-294,854 |